Medicare Advantage TRT Coverage Rules Tighten in 2026

Medicare Advantage plans quietly rolled out a major change to how they review testosterone replacement therapy claims in 2026. Most MA organizations are now using InterQual evidence-based criteria to determine coverage, which means the approval rules are more standardized than ever -- but also more exacting.

For men on Medicare who need TRT, the new framework is both good news and bad news. Good: if you meet the criteria, approvals are faster and more predictable. Bad: the documentation bar is higher, and idiopathic low testosterone (the most common form) is still frequently denied.

Key Takeaways

• Most Medicare Advantage plans adopted InterQual criteria for TRT review in 2026, standardizing approval rules across plans
• Coverage requires two morning testosterone readings below 300 ng/dL, documented symptoms, and a confirmed hypogonadism diagnosis
• Injection TRT costs $5-30/month after approval through Medicare Part D; prior authorization is required on most plans
• Idiopathic low testosterone still faces higher denial rates -- the FDA's April 2026 indication expansion has not yet changed Medicare rules
• Cash-pay through online TRT clinics costs $99-250/month and avoids the 2-6 week approval process
• Medicare Advantage 2026 in-network out-of-pocket max is $9,350

What Actually Changed in 2026

Until this year, Medicare Advantage plans used a patchwork of internal criteria to approve or deny TRT. One plan might require testosterone under 250 ng/dL; another might accept 300 ng/dL. Some required two tests, others accepted one. Appeal outcomes were unpredictable.

In 2026, most MA organizations moved to InterQual, a clinical decision-support tool published by Change Healthcare (now part of Optum). InterQual provides standardized, evidence-based criteria for thousands of conditions, including hypogonadism and TRT.

The shift matters because InterQual is transparent. The criteria are published, vetted by clinical panels, and updated annually. Plans using InterQual have to document exactly why a case was approved or denied against those criteria -- not just cite an opaque internal policy.

The Practical Effect

If you meet InterQual TRT criteria cleanly, you will likely get approved faster. If your case is borderline or missing documentation, the denial will be more specific -- which makes appeals easier to target.

The downside: InterQual criteria are stricter than many previous plan-specific rules. Men whose cases used to slip through on "physician discretion" may now get formal denials.

The 2026 InterQual TRT Criteria (What You Need)

The specific InterQual criteria for TRT coverage in 2026 require documented evidence across four domains. Miss any one and the plan can deny.

1. Laboratory Confirmation

• Two morning total testosterone tests below 300 ng/dL (some plans use 264 ng/dL as the cutoff based on 2018 Endocrine Society guidelines)
• Tests must be taken at least 7 days apart
• Both samples must be drawn before 10 AM (testosterone peaks in the morning and drops throughout the day)
• If total testosterone is borderline (280-350 ng/dL), free testosterone below the reference range can support the diagnosis
• Fasting is not strictly required but is preferred for reproducibility

The "two tests" requirement is the most common stumbling block. Afternoon draws, same-day repeats, and single-sample diagnoses all fail InterQual review. See our guide on how to test testosterone correctly for the exact protocol.

2. Symptom Documentation

The prescribing clinician must document specific symptoms consistent with androgen deficiency. InterQual accepts:

• Decreased libido or sexual function
• Fatigue affecting daily activities
• Depressed mood or loss of motivation
• Reduced exercise tolerance
• Loss of muscle mass or strength
• Erectile dysfunction unresponsive to PDE5 inhibitors alone

Vague notes like "patient reports feeling tired" often fail. Specific, quantified symptom descriptions pass. Our low testosterone symptoms guide lists the exact language clinicians should use.

3. Ruling Out Reversible Causes

This is where many cases get denied. The plan wants evidence the clinician evaluated reversible contributors before prescribing TRT:

Reversible Cause	Required Workup
Obesity	BMI documented; weight loss counseling attempted if BMI >30
Medication effects	Review of opioids, chronic glucocorticoids, antipsychotics
Sleep apnea	Screening questionnaire or referral if indicated
Excessive alcohol	History documented
Pituitary pathology	LH, FSH, prolactin tested; MRI if prolactin elevated
Hemochromatosis	Iron studies if family history or suspicion

Many men have one or more of these factors. The plan does not require you to resolve them first -- but it does require the clinician to document they were considered.

4. Classical Hypogonadism Diagnosis

This is the biggest barrier for most men. InterQual requires the diagnosis to fit into primary or secondary hypogonadism:

• Primary (testicular): Low testosterone with elevated LH and FSH. Causes include Klinefelter syndrome, testicular injury, chemotherapy, radiation.
• Secondary (pituitary): Low testosterone with low or inappropriately normal LH and FSH. Causes include pituitary adenoma, Kallmann syndrome, traumatic brain injury.

"Idiopathic hypogonadism" -- low testosterone with no identifiable cause, which describes most age-related cases -- is not a covered diagnosis under current InterQual criteria. This is a significant gap. The FDA's April 16, 2026 announcement inviting new drug applications for idiopathic hypogonadism could change this in 12-24 months, but Medicare has not yet updated its criteria.

What TRT Costs on Medicare in 2026

Once approved, the cost structure depends on which Medicare pathway covers your prescription.

Medicare Part D (Most Common)

Most injection and oral testosterone products are covered under Part D once prior authorization is approved. Typical 2026 monthly costs:

TRT Form	Typical Part D Copay	Notes
Testosterone cypionate (injection)	$5-30	Generic, usually Tier 1-2
Testosterone enanthate (injection)	$10-40	Generic, Tier 2
Testosterone gel (generic)	$30-80	Tier 2-3
Testosterone patch	$50-150	Tier 3
Oral testosterone (KYZATREX, Jatenzo)	$100-300	Tier 3-4, preferred brand only

Generic injectable cypionate or enanthate is almost always the cheapest option on Medicare. See our guide on testosterone cypionate vs enanthate to understand the clinical differences.

Medicare Part B

Some MA plans cover testosterone administered in a physician's office under Part B. This is less common for TRT and mostly applies to pellet implants (Testopel) administered every 3-6 months in-clinic. Part B typically requires 20% coinsurance after the deductible.

Out-of-Pocket Maximums

Medicare Advantage plans have annual out-of-pocket limits that cap your total spending:

• In-network only: $9,350 in 2026 (up from $8,850 in 2025)
• Combined in/out-of-network: $14,000 in 2026

For TRT specifically, most men never approach these limits because covered injection protocols are inexpensive. The caps matter more for related costs like bloodwork, consults, and comorbidity management.

The Denial Problem

Even with standardized criteria, TRT denials remain common on Medicare Advantage. Industry estimates suggest 15-25% of initial TRT prior authorization requests are denied.

Top 5 Denial Reasons in 2026

1. Only one testosterone test below threshold -- plans require two separate morning draws. Single-sample diagnoses are the leading denial reason.
2. Missing symptom documentation -- labs alone are not enough. The clinician note must explicitly link lab values to clinical symptoms.
3. Afternoon testosterone measurement -- samples drawn after 10 AM are often rejected because testosterone drops throughout the day.
4. No workup for reversible causes -- missing LH/FSH, prolactin, or BMI documentation triggers denial.
5. Idiopathic diagnosis -- coding the diagnosis as "testosterone deficiency" or "age-related hypogonadism" without specifying primary or secondary hypogonadism.

How to Appeal Successfully

Most Medicare Advantage TRT denials are reversible on appeal. The key is addressing the specific denial reason, not resubmitting the same documentation.

1. Request the denial letter in writing -- it must state the specific InterQual criterion that was not met
2. Get a second morning testosterone test if only one was on file
3. Have your clinician write a symptom-specific addendum referencing the exact InterQual language
4. Document the reversible-cause workup even if nothing was found
5. Request peer-to-peer review -- a clinician-to-clinician conversation often resolves borderline denials

MA plans must respond to expedited appeals within 72 hours and standard appeals within 7 days under 2026 rules.

Medicare vs Cash-Pay: Which Is Actually Cheaper?

The math is less obvious than it looks. Medicare covers most of the drug cost once approved, but the total experience has real costs beyond the copay.

Medicare Pathway Total Cost (Annual, Approved Case)

Cost Category	Typical Amount
TRT medication (generic injection)	$60-360
Quarterly bloodwork copays	$40-120
Office visits (4/year)	$80-160
Prior auth renewal admin	Time cost
Total annual	$180-640

Cash-Pay Online TRT Clinic (Annual)

Cost Category	Typical Amount
Monthly subscription (medication + consults + labs)	$1,188-3,000
Additional labs if requested	$0-200
Total annual	$1,188-3,200

On pure dollars, Medicare wins by $1,000-2,500 per year for men who qualify. The comparison changes when you factor in:

• Approval time: Medicare takes 2-6 weeks for initial approval. Online clinics start treatment in 5-10 days.
• Protocol flexibility: Medicare typically covers standard weekly or biweekly injections. Online clinics routinely offer twice-weekly or daily subcutaneous protocols, which produce steadier levels. See injection frequency comparison.
• Ancillary medications: HCG, anastrozole, and enclomiphene are often not covered by Medicare for TRT-related use. Online clinics include them in monthly subscriptions when clinically indicated.
• Appeal burden: Denied Medicare cases require persistence. Cash-pay has no prior authorization.

The Decision Framework

Choose Medicare if:

• You have classical primary or secondary hypogonadism (clear diagnosis)
• You are comfortable with standard injection protocols
• You are on fixed income and the cost difference matters
• You have time for the prior authorization process

Choose cash-pay if:

• Your diagnosis is idiopathic or borderline
• You want a non-standard protocol (daily subQ, HCG add-on, enclomiphene)
• You need treatment started quickly
• You value the telehealth experience and ancillary support

For a deeper comparison, see our TRT with insurance vs without breakdown.

What the FDA Announcement Means for Medicare

The April 16, 2026 FDA move to invite sNDAs for testosterone in idiopathic hypogonadism will eventually affect Medicare coverage -- but not quickly.

The timeline:

Milestone	Expected Timeframe
FDA sNDA submissions	Summer to Fall 2026
Standard FDA review	10 months
First indication approvals	Late 2027 to early 2028
InterQual criteria update	6-12 months after FDA approval
Medicare plan adoption	12-18 months after criteria update

In practical terms, men with idiopathic low testosterone on Medicare are looking at 2028-2029 before formal coverage expansion. Until then, the same workarounds apply: document symptoms thoroughly, pursue peer-to-peer appeals, or move to cash-pay if coverage fails.

Read our analysis of the FDA idiopathic hypogonadism pathway for the full regulatory context.

Action Steps If You Are on Medicare

1. Confirm your plan's criteria. Call member services and ask whether your MA plan uses InterQual for TRT review. Most do in 2026, but some still use proprietary criteria.
2. Get two morning tests on the books. Before requesting treatment, have two testosterone tests drawn before 10 AM at least a week apart. This solves the leading denial reason before it happens.
3. Document symptoms with your clinician. Be specific. "Libido reduced from weekly to monthly" reads better on review than "decreased libido."
4. Request the InterQual criteria in writing. Members have a right to see the specific criteria the plan uses. This prevents surprise denials.
5. Compare cash-pay options in parallel. If your case is borderline or your clinician is uncomfortable with the prior auth process, compare online TRT clinics before you start the Medicare process. Knowing your cash-pay fallback shortens decision time if a denial comes.
6. Plan for appeals. Assume a 15-25% chance of initial denial. Have your clinician pre-commit to writing an appeal letter if needed. Most denials are reversible.

Bottom Line

Medicare Advantage TRT coverage in 2026 is more predictable than ever, but also more exacting. The InterQual standardization is a net positive for men with clean-cut classical hypogonadism cases. It is a net negative for the much larger group of men with idiopathic low testosterone, who still face frequent denials.

The FDA's April 2026 indication expansion will eventually close that gap. For now, the practical reality is unchanged: if your diagnosis fits InterQual, use Medicare and save money. If it does not, cash-pay online TRT clinics remain the fastest path to treatment.

References

1. Centers for Medicare & Medicaid Services. Medicare Advantage and Part D Final Rule Contract Year 2026.
2. Change Healthcare. InterQual Clinical Criteria for Testosterone Replacement Therapy. 2026 Edition.
3. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018.
4. FDA. FDA Takes Step Forward on Testosterone Therapy for Men. Press Announcement, April 16, 2026.
5. UnitedHealthcare. Commercial Medical Policy: Testosterone Replacement or Supplementation Therapy. 2026.
6. American Urological Association. Evaluation and Management of Testosterone Deficiency Guideline. 2024 Amendment.
7. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117.
8. Medicare.org. Does Medicare Cover Testosterone Replacement Therapy? 2026 Update.